Journal
LANCET ONCOLOGY
Volume 12, Issue 9, Pages 905-912Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70056-0
Keywords
-
Categories
Funding
- National Cancer Institute [U01 CA 121947]
- National Institute of Allergy and Infectious Disease [U01 AI 069465, AI 068636]
- GlaxoSmithKline
- Concordia Pharmaceuticals
Ask authors/readers for more resources
Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available